Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies-Reference-Cited by-同舟云学术

Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies

Published:2021-10 Issue: Volume:99 Page:107985
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Clot Pierre-François,Kamal Mohamed,Sun Jing,Xu Christine,Kong Fangyuan,Gu Yongzhen,Yang Na,Yin WeiHong,Chen Bing,Ming Jeffrey E.,Yuan Yaozong

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference27 articles.

1. Atopic dermatitis;Weidinger;Nat. Rev. Dis. Primers.,2018

2. Atopic dermatitis endotypes and implications for targeted therapeutics;Czarnowicki;J. Allergy Clin. Immunol.,2019

3. Phenotypic analysis of atopic dermatitis in children aged 1–12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence;Guo;J. Eur. Acad. Dermatol. Venereol.,2019

4. Prevalence of atopic dermatitis in Chinese children aged 1–7 ys;Guo;Sci. Rep.,2016

5. The prevalence of atopic dermatitis and chronic spontaneous urticaria are associated with parental socioeconomic status in adolescents in China;Xiao;Acta. Derm. Venereol.,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a recombinant humanized anti-IL-4Rα monoclonal antibody CM310 in serum and its application to pharmacokinetic study in Sprague-Dawley Rats;Analytical Biochemistry;2024-11

2. Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity;Journal of the European Academy of Dermatology and Venereology;2024-07-31

3. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis;Advances in Therapy;2024-06-04

4. Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis;Clinical and Translational Science;2023-10-17

5. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis;Allergy;2022-07-29